Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965137 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL30789181 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL30381729 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL145392 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL1580111 | 0.90 | PTPRA (0.82) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL1580112 | 0.90 | PTPRA (0.82) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL22288108 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL20931031 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL22288107 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL7380735 | 0.85 | PTPRA (0.73) | PTPRACYP2C19KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034248-B1 | COMPOSITE BIOMARKER FOR CANCER THERAPY | BRISTOL MYERS SQUIBB CO (US) | 2026-05-20 | — | — | EP | claimed |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-12 | — | — | US | claimed |
| WO-2008068621-A2 | COMBINATION PRODUCT WITH IDO INHIBITOR AND TUMOR TARGETED IFN-GAMMA | MOLMED SPA (IT) | 2008-06-12 | — | — | WO | claimed |
| EP-3906415-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-20260083725-A1 | SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER | INST NAT SANTE RECH MED (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-4713371-A1 | ANTI-CATHEPSIN-D ANTIBODIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-20260061031-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY | INST NAT SANTE RECH MED (FR) | 2026-03-05 | — | — | US | disclosed |
| EP-4689658-A1 | METHOD FOR DISCRIMINATING MONO-IMMUNOTHERAPY FROM COMBINED IMMUNOTHERAPY IN CANCERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035471-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | INST NAT SANTE RECH MED (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20260029406-A1 | PROTEIN IDENTIFICATION VIA PEPTIDE BARCODES | Quantum-Si Incorporated (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260023081-A1 | SOLID PHASE LIBRARY PREPARATION FOR POLYPEPTIDE SEQUENCING | Quantum-Si Incorporated (US) | 2026-01-22 | — | — | US | disclosed |
| US-20090081155-A1 | Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2009-03-26 | — | — | US | disclosed |
| EP-1981534-A2 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | Medical College of Georgia Research Institute, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-101265259-A | Novel IDO inhibitor and its usage method | LANKENAU INST MEDICAL RES (US) | 2008-09-17 | — | — | CN | disclosed |
| CN-101265254-A | Novel IDO inhibitor and its usage method | LANKENAU INST MEDICAL RES (US) | 2008-09-17 | — | — | CN | disclosed |
| EP-1937303-A2 | THE INDUCTION OF INDOLEAMINE 2,3-DIOXYGENASE IN DENDRITIC CELLS BY TLR LIGANDS AND USES THEREOF | Medical College Of Georgia Research Institute, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008068621-A2 | COMBINATION PRODUCT WITH IDO INHIBITOR AND TUMOR TARGETED IFN-GAMMA | MOLMED SPA (IT) | 2008-06-12 | — | — | WO | disclosed |
| WO-2007081878-A2 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007050405-A2 | THE INDUCTION OF INDOLEAMINE 2,3-DIOXYGENASE IN DENDRITIC CELLS BY TLR LIGANDS AND USES THEREOF | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20040234623-A1 | Anticancer agents; infection; immunosuppressants | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061031-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY | CD274, PDCD1, ICOS | PTPRA 1833/4885CYP2C19 3111/4885KMT2A 3766/4885 |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | IDO1, IDO2, GPR119 | PTPRA 2977/4885CYP2C19 313/4885KMT2A 1002/4885 |
| US-20260083725-A1 | SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER | SCTR, NGFR, SIGMAR1 | PTPRA 355/4885CYP2C19 4875/4885KMT2A 4372/4885 |
| US-20260029406-A1 | PROTEIN IDENTIFICATION VIA PEPTIDE BARCODES | MAX, DNMT3A, SET | PTPRA 1651/4885CYP2C19 4218/4885KMT2A 100/4885 |
| US-20260023081-A1 | SOLID PHASE LIBRARY PREPARATION FOR POLYPEPTIDE SEQUENCING | SPPL2B, SPPL2A, CTRC | PTPRA 4759/4885CYP2C19 1876/4885KMT2A 1552/4885 |
| US-20260035471-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | CD274, PDCD1LG2, PDCD1 | PTPRA 541/4885CYP2C19 4543/4885KMT2A 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.